All 39 patients were evaluable. No patient had a complete response, 16 had partial response (PR), 14 had stable disease, and 9 had progressive disease. The ORR was 41.0% (95% confidence interval (CI) 24.9–57.2%), and the DCR was 76.9% (95% CI 63.1–90.8%). The median time to response was 1.70 (range 1.40–3.00) months (m).